MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to host an in-person Clinical Showcase on Tuesday, November 12, 2024, at the Nasdaq MarketSite in Times Square, New York City, from 10 a.m. to noon ET. The event will highlight significant advancements in the company’s gene therapy trials, aimed at treating various eye diseases.
Attendees will receive updates on Ocugen’s ongoing trials, including the Phase 3 liMeliGhT study for retinitis pigmentosa and data from Phase 1/2 trials for retinitis pigmentosa and Leber congenital amaurosis. Preliminary safety and efficacy results from the Phase 1/2 OCU410 ArMaDa trial for geographic atrophy will also be discussed, along with progress from the OCU410ST GARDian study targeting Stargardt disease.
Additionally, Ocugen will provide an overview of their biologic candidate OCU200 for diabetic macular edema, with plans to initiate a Phase I trial this quarter.
Key presenters from Ocugen include Dr. Shankar Musunuri, CEO and Co-founder, Dr. Huma Qamar, Chief Medical Officer, Dr. Arun Upadhyay, Chief Scientific Officer, and Mike Shine, Senior Vice President of Commercial. The event will also feature insights from prominent study investigators such as Dr. Benjamin Bakall from Associated Retina Consultants, Dr. Lejla Vajzovic of Duke Eye Center, and Dr. Syed M. Shah from Gundersen Health.
The program will conclude with a patient panel, featuring individuals participating in Ocugen’s clinical trials, offering personal perspectives on their experiences and the potential impact of these therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.